A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Bendamustine (Primary) ; Cytarabine; Etoposide; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 08 Jun 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.
- 08 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 16 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.